C12N 2501/2304
Interleukin-4
Official title: Interleukin-4 (IL-4)
C12N2501/2304 (Interleukin-4) appears on 149 US grants and 416 published applications in this corpus.
Search patents in C12N- Granted patents
- 149
- Published applications
- 416
- Assignees
- 242
- Inventors
- 832
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 1 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 3 |
| 2009 | 0 | 3 |
| 2010 | 0 | 3 |
| 2011 | 3 | 5 |
| 2012 | 3 | 4 |
| 2013 | 4 | 8 |
| 2014 | 4 | 12 |
| 2015 | 3 | 20 |
| 2016 | 9 | 15 |
| 2017 | 9 | 25 |
| 2018 | 13 | 14 |
| 2019 | 8 | 40 |
| 2020 | 8 | 29 |
| 2021 | 15 | 43 |
| 2022 | 13 | 48 |
| 2023 | 14 | 36 |
| 2024 | 20 | 39 |
| 2025 | 14 | 36 |
| 2026 | 7 | 29 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fixed ratio ex vivo activated mixed lymphocyte products for use in the treatment of cancer22 Sep 2026US 12,742,153 B2Children's National Medical Center
- Tumor immunotherapy composition based on antigen-presenting cells activated by attenuated listeria monocytogenes, preparation method therefor and application thereof11 Aug 2026US 12,702,681 B2Shanghai RoyalTech Med CO., Ltd
- C-met and TMX2 antibodies14 Apr 2026US 12,600,786 B2R.G.C.C. Holdings AG
- Modified macrophages, compositions and uses thereof14 Apr 2026US 12,600,949 B2Duogenic Stemcells Corporation
- Preparation of a therapeutic composition for treating autoimmune diseases31 Mar 2026US 12,589,113 B2Avotres, Inc.
- Metabolically enhanced vd1 t cells and uses thereof8 Oct 2026US 2026/0308518 A1
- Targeted lnp compositions for in vivo immune cell engineering and methods of use thereof17 Sep 2026US 2026/0274918 A1CREATE Medicines, Inc.
- Extracellular vesicles loaded with polydopamine nanoparticles, and preparation method27 Aug 2026US 2026/0248848 A1The Second Medical Center?Chinese PLA General Hospital
- Prostate-specific membrane antigen targeted nf-kb p50-deficient immature myeloid cells27 Aug 2026US 2026/0248849 A1The Johns Hopkins University
- Immune cell-derived secretome20 Aug 2026US 2026/0243757 A1Agency for Science, Technology and Research
Most cited
By later US patents
- Integration-free human induced pluripotent stem cells from blood73US 8,048,675 B1iPierian, Inc. · 2011
- Yolk sac stem cells and their uses57US 5,744,347 AOhio University/Edison Biotechnology Institute · 1998
- Method for proliferation of antigen-specific T cells54US 9,476,028 B2Immunicum AB · 2016
- Remnant tumor infiltrating lymphocytes and methods of preparing and using the same27US 11,220,670 B2Iovance Biotherapeutics, Inc. · 2022
- Remnant tumor infiltrating lymphocytes and methods of preparing and using the same27US 11,293,009 B2Iovance Biotherapeutics, Inc. · 2022